Thursday, September 22, 2016

Canasa


Canasa is a brand name of mesalamine, approved by the FDA in the following formulation(s):


CANASA (mesalamine - suppository; rectal)



  • Manufacturer: AXCAN

    Approval date: November 5, 2004

    Strength(s): 1GM [RLD]

Has a generic version of Canasa been approved?


No. There is currently no therapeutically equivalent version of Canasa available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Canasa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Canasa.

See also...

  • Canasa Suppositories Consumer Information (Wolters Kluwer)
  • Canasa rectal Consumer Information (Cerner Multum)
  • Canasa Rectal Advanced Consumer Information (Micromedex)
  • Mesalamine Controlled-Release Capsules Consumer Information (Wolters Kluwer)
  • Mesalamine Delayed-Release Tablets Consumer Information (Wolters Kluwer)
  • Mesalamine Enema Consumer Information (Wolters Kluwer)
  • Mesalamine Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Mesalamine Suppositories Consumer Information (Wolters Kluwer)
  • Mesalamine Consumer Information (Cerner Multum)
  • Mesalamine rectal Consumer Information (Cerner Multum)
  • Mesalamine Advanced Consumer Information (Micromedex)
  • Mesalamine Rectal Advanced Consumer Information (Micromedex)
  • SfRowasa Advanced Consumer Information (Micromedex)
  • Mesalamine AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Stavzor


Stavzor is a brand name of valproic acid, approved by the FDA in the following formulation(s):


STAVZOR (valproic acid - capsule, delayed release; oral)



  • Manufacturer: BANNER PHARMACAPS

    Approval date: July 29, 2008

    Strength(s): 125MG, 250MG, 500MG [RLD]

Has a generic version of Stavzor been approved?


No. There is currently no therapeutically equivalent version of Stavzor available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Stavzor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Stavzor.

See also...

  • Stavzor Consumer Information (Drugs.com)
  • Stavzor Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Stavzor Consumer Information (Cerner Multum)
  • Stavzor Advanced Consumer Information (Micromedex)
  • Valproate Consumer Information (Wolters Kluwer)
  • Valproate Syrup Consumer Information (Wolters Kluwer)
  • Valproic Acid Consumer Information (Wolters Kluwer)
  • Valproic Acid Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Valproic Acid Syrup Consumer Information (Wolters Kluwer)
  • Valproic acid Consumer Information (Cerner Multum)
  • Alti-Valproic Advanced Consumer Information (Micromedex)
  • Depakote Advanced Consumer Information (Micromedex)
  • Depakote DR Advanced Consumer Information (Micromedex)
  • Depakote ER Advanced Consumer Information (Micromedex)
  • Depakote Sprinkles Advanced Consumer Information (Micromedex)
  • Epiject Iv Advanced Consumer Information (Micromedex)
  • Valproate sodium Intravenous Advanced Consumer Information (Micromedex)
  • Valproic acid Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Soma


Soma is a brand name of carisoprodol, approved by the FDA in the following formulation(s):


SOMA (carisoprodol - tablet; oral)



  • Manufacturer: MEDA PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 350MG [AA]


  • Manufacturer: MEDA PHARMS

    Approval date: September 13, 2007

    Strength(s): 250MG [RLD]

Has a generic version of Soma been approved?


A generic version of Soma has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Soma and have been approved by the FDA:


carisoprodol tablet; oral



  • Manufacturer: ADVENT PHARMS

    Approval date: June 7, 2005

    Strength(s): 350MG [AA]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: August 6, 2009

    Strength(s): 350MG [AA]


  • Manufacturer: COREPHARMA

    Approval date: September 21, 2000

    Strength(s): 350MG [AA]


  • Manufacturer: MIRROR PHARMS

    Approval date: October 22, 2008

    Strength(s): 350MG [AA]


  • Manufacturer: MUTUAL PHARM

    Approval date: October 17, 1991

    Strength(s): 350MG [AA]


  • Manufacturer: PROSAM LABS

    Approval date: March 7, 1997

    Strength(s): 350MG [AA]


  • Manufacturer: SUN PHARM INDS LTD

    Approval date: February 27, 2007

    Strength(s): 350MG [AA]


  • Manufacturer: VINTAGE PHARMS

    Approval date: September 8, 1997

    Strength(s): 350MG [AA]


  • Manufacturer: WATSON LABS

    Approval date: April 20, 1982

    Strength(s): 350MG [AA]


  • Manufacturer: WEST WARD

    Approval date: January 24, 1996

    Strength(s): 350MG [AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Soma. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Soma.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • September 13, 2010 - NEW PRODUCT

See also...

  • Soma Consumer Information (Drugs.com)
  • Soma Consumer Information (Wolters Kluwer)
  • Soma Consumer Information (Cerner Multum)
  • Soma Advanced Consumer Information (Micromedex)
  • Carisoprodol Consumer Information (Drugs.com)
  • Carisoprodol Consumer Information (Wolters Kluwer)
  • Carisoprodol Consumer Information (Cerner Multum)
  • Carisoprodol Advanced Consumer Information (Micromedex)
  • Carisoprodol AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Rowasa


Rowasa is a brand name of mesalamine, approved by the FDA in the following formulation(s):


ROWASA (mesalamine - enema; rectal)



  • Manufacturer: MEDA PHARMS

    Approval date: December 24, 1987

    Strength(s): 4GM/60ML [RLD][AB]

Has a generic version of Rowasa been approved?


Yes. The following products are equivalent to Rowasa:


mesalamine enema; rectal



  • Manufacturer: PERRIGO ISRAEL

    Approval date: September 17, 2004

    Strength(s): 4GM/60ML [AB]


  • Manufacturer: TEVA

    Approval date: September 30, 2004

    Strength(s): 4GM/60ML [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rowasa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Rowasa.

See also...

  • Rowasa Enema Consumer Information (Wolters Kluwer)
  • Rowasa rectal Consumer Information (Cerner Multum)
  • Rowasa Advanced Consumer Information (Micromedex)
  • Mesalamine Controlled-Release Capsules Consumer Information (Wolters Kluwer)
  • Mesalamine Delayed-Release Tablets Consumer Information (Wolters Kluwer)
  • Mesalamine Enema Consumer Information (Wolters Kluwer)
  • Mesalamine Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Mesalamine Suppositories Consumer Information (Wolters Kluwer)
  • Mesalamine Consumer Information (Cerner Multum)
  • Mesalamine rectal Consumer Information (Cerner Multum)
  • Mesalamine Advanced Consumer Information (Micromedex)
  • Mesalamine Rectal Advanced Consumer Information (Micromedex)
  • SfRowasa Advanced Consumer Information (Micromedex)
  • Mesalamine AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Somatuline Depot


Somatuline Depot is a brand name of lanreotide, approved by the FDA in the following formulation(s):


SOMATULINE DEPOT (lanreotide acetate - injectable; subcutaneous)



  • Manufacturer: IPSEN PHARMS

    Approval date: August 30, 2007

    Strength(s): EQ 120MG BASE [RLD], EQ 60MG BASE [RLD], EQ 90MG BASE [RLD]

Has a generic version of Somatuline Depot been approved?


No. There is currently no therapeutically equivalent version of Somatuline Depot available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Somatuline Depot. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Sustained release of peptides from pharmaceutical compositions
    Patent 5,595,760
    Issued: January 21, 1997
    Inventor(s): Cherif-Cheikh; Roland
    Assignee(s): Delab
    The invention features a method of administering a peptide to a patient and delivering the peptide continuously over an extended period of time of at least three days by obtaining a solid pharmaceutical composition including a soluble, gelable salt of the peptide and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier, and parenterally administering the solid composition to the patient in one injection, wherein the solid composition automatically forms a gel after interaction with the patient's bodily fluids and releases the peptide continuously within the patient over an extended period of at least three days.
    Patent expiration dates:

    • March 8, 2020
      ✓ 
      Patent use: METHOD OF ADMINISTERING LANREOTIDE ACETATE
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • August 30, 2012 - NEW CHEMICAL ENTITY

    • March 4, 2014 - EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG

    • August 30, 2014 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Somatuline Depot Consumer Information (Drugs.com)
  • Somatuline Depot Consumer Information (Wolters Kluwer)
  • Somatuline Depot Consumer Information (Cerner Multum)
  • Somatuline Depot Advanced Consumer Information (Micromedex)
  • Somatuline Depot AHFS DI Monographs (ASHP)
  • Lanreotide Consumer Information (Wolters Kluwer)
  • Lanreotide Consumer Information (Cerner Multum)
  • Lanreotide Subcutaneous Advanced Consumer Information (Micromedex)
  • Lanreotide Acetate AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Conray


Conray is a brand name of iothalamate, approved by the FDA in the following formulation(s):


CONRAY (iothalamate meglumine - injectable; injection)



  • Manufacturer: MALLINCKRODT

    Approved Prior to Jan 1, 1982

    Strength(s): 60% [RLD]

Has a generic version of Conray been approved?


No. There is currently no therapeutically equivalent version of Conray available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Conray. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Conray.

See also...

    Posted by at No comments:
    Labels:

    Ritalin


    See also: Generic Ritalin LA, Generic Ritalin-SR


    Ritalin is a brand name of methylphenidate, approved by the FDA in the following formulation(s):


    RITALIN (methylphenidate hydrochloride - tablet; oral)



    • Manufacturer: NOVARTIS

      Approved Prior to Jan 1, 1982

      Strength(s): 10MG [AB], 20MG [RLD][AB], 5MG [AB]

    Has a generic version of Ritalin been approved?


    Yes. The following products are equivalent to Ritalin:


    methylphenidate hydrochloride tablet; oral



    • Manufacturer: MALLINCKRODT

      Approval date: November 27, 1998

      Strength(s): 10MG [AB], 20MG [AB], 5MG [AB]


    • Manufacturer: UCB INC

      Approved Prior to Jan 1, 1982

      Strength(s): 10MG [AB], 20MG [AB], 5MG [AB]


    • Manufacturer: WATSON LABS

      Approval date: August 29, 1997

      Strength(s): 10MG [AB], 20MG [AB], 5MG [AB]

    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ritalin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents

    There are no current U.S. patents associated with Ritalin.

    See also...

    • Ritalin Consumer Information (Drugs.com)
    • Ritalin Consumer Information (Wolters Kluwer)
    • Ritalin Consumer Information (Cerner Multum)
    • Ritalin Advanced Consumer Information (Micromedex)
    • Methylphenidate Consumer Information (Drugs.com)
    • Methylphenidate Consumer Information (Wolters Kluwer)
    • Methylphenidate Chewable Tablets Consumer Information (Wolters Kluwer)
    • Methylphenidate Controlled-Release Capsules Consumer Information (Wolters Kluwer)
    • Methylphenidate Controlled-Release Tablets Consumer Information (Wolters Kluwer)
    • Methylphenidate Extended-Release Capsules Consumer Information (Wolters Kluwer)
    • Methylphenidate Extended-Release Tablets Consumer Information (Wolters Kluwer)
    • Methylphenidate Solution Consumer Information (Wolters Kluwer)
    • Methylphenidate System Consumer Information (Wolters Kluwer)
    • Methylphenidate Consumer Information (Cerner Multum)
    • Methylphenidate transdermal Consumer Information (Cerner Multum)
    • Methylphenidate Oral, Transdermal Advanced Consumer Information (Micromedex)
    • Methylphenidate Transdermal Advanced Consumer Information (Micromedex)
    • Methylphenidate Hydrochloride AHFS DI Monographs (ASHP)
    Posted by at No comments:
    Labels:
    Subscribe to: Posts (Atom)